Partner Headlines - MDVN

  1. Fast Money Halftime Report Final Trade From September 12

    Benzinga
  2. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  3. Stifel Raises Medivation Inc Price Target

    Benzinga
  4. Stocks Hitting 52-Week Highs

    Benzinga
  5. A Few Reasons Why Investors Should Consider Dendreon for Their ...

    GuruFocus
  6. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD
  7. Benzinga's Volume Movers

    Benzinga
  8. Medivation Announces Change in Executive Management Team; Dawn ...

    Benzinga
  9. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  10. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga
  11. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer ...

    Benzinga
  12. Benzinga's Top Upgrades

    Benzinga
  13. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga
  14. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as ...

    Benzinga
  15. Morning Market Movers

    Benzinga
  16. Stocks To Watch For April 1, 2014

    Benzinga
  17. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, ...

    Benzinga
  18. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® ...

    Benzinga
  19. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  20. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga
  21. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  22. Benzinga's Top #PreMarket Losers

    Benzinga
  23. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  24. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga
  25. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro ...

    Benzinga
  26. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  27. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts ...

    Benzinga
  28. Stocks Hitting 52-Week Highs

    Benzinga
  29. Benzinga's Top #PreMarket Gainers

    Benzinga
  30. Medivation and Astellas Announce Final Results From the Phase ...

    Benzinga
  31. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line ...

    Benzinga
  32. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide ...

    Benzinga
  33. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts
  34. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; ...

    Benzinga
  35. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga
  36. Medivation Bulls Load Up on Call Options

    SchaeffersResearch
  37. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga
  38. Medivation, Inc. (MDVN) President and CEO David Hung sells 1 ...

    GuruFocus
  39. Benzinga's Top Initiations

    Benzinga
  40. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD
  41. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  42. UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

    Benzinga
  43. Medivation Effects 2-for-1 Stock Split

    Benzinga
  44. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga
  45. US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant ...

    Benzinga
  46. Medivation Reports 2-for-1 Forward Split of Common Stock

    Benzinga
  47. Andreas Halvorsen Buys 2 Million Shares of Medivation

    GuruFocus
  48. Medivation Inc. (MDVN) President and CEO David Hung sells 25, ...

    GuruFocus
  49. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  50. Stocks Hitting 52-Week Highs

    Benzinga
  51. Health Care Sector Wrap

    FoxBusiness
  52. Four Winning Trades Based on Analyst Calls

    Benzinga
  53. Medivation Bull Looks to Cash In on Continued Rally

    SchaeffersResearch
  54. Analyst Upgrades: MDVN, SCHN, and STI

    SchaeffersResearch
  55. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  56. Citigroup Reiterates Buy Rating, $129 PT for Medivation

    Benzinga
  57. Medivation and Astellas Announce Enzalutamide Data

    Benzinga
  58. Crazy Action in Medivation After Negative StreetSweeper Post

    Benzinga
  59. Global Fears and Small Caps: How Much of an Impact?

    Benzinga
  60. Social Media Outlook for Tuesday 15 (DKS, MDVN, BBY, ACOM)

    Benzinga
  61. GlaxoSmithKline, Vertex Point To Biotech Strength

    IBD
  62. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  63. Will Johnson & Johnson Cure Cancer?

    Benzinga
  64. Options Players Show a Preference for Medivation Puts

    SchaeffersResearch
  65. Notable Put Options Activity in Medivation

    Benzinga
  66. Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, ...

    GuruFocus
  67. Medivation's Stellar Technical Performance Entices Option Bulls

    SchaeffersResearch
  68. Benzinga's M&A Chatter for Wednesday February 1, 2012

    Benzinga
  69. Medivation Soars on Phase III Trial Data; Stock Up 21%

    Benzinga
  70. Jefferies Raises PT on Medivation to $95

    Benzinga
  71. Wedbush Raises PT on Medivation to $81

    Benzinga
  72. Medivation and Astellas Announce Positive Results From the Phase ...

    Benzinga
  73. Upgrades & Downgrades: AZO, MDVN, POT, TSLA, and UA

    SchaeffersResearch
  74. Gilead, Celgene Join Big Pharma On M&A Front

    IBD
  75. Alzheimer's drug test halted

    IBD
  76. Best Biotech Stocks of 2011

    Benzinga
  77. Options Players Get Bearish with Medivation Puts

    SchaeffersResearch
  78. Notable Put Options Activity in Medivation

    Benzinga
  79. Put Volume Heats Up as Medivation Surges to a New High

    SchaeffersResearch
Trading Center